CDXS stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, BlackRock Inc., Pier Capital LLC, Nuveen Asset Management LLC, Morgan Stanley, William Blair Investment Management LLC, Dimensional Fund Advisors LP, and Castleark Management LLC. +0.45 (+1.63%) DATA AS OF Feb 03, 2021. What this means: InvestorsObserver gives Codexis Inc (CDXS) an overall rank of 44, which is below average. Export data to Excel for your own analysis. Never miss a profitable trade. View live CODEXIS INC chart to track its stock's price action. The official website for Codexis is www.codexis.com. Our Accessibility Statement | Terms of Service | Do Not Sell My Information. Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch. The stock is rated as a Hold by none analyst(s), 8 recommend it as a Buy and no body called the CDXS stock Outperform. View which stocks are hot on social media with MarketBeat's trending stocks report. CDXS stock forecast Our latest prediction for Codexis Inc.'s stock price was made on the Aug. 20, 2019 when the stock price was at 13.01$.. Codexis has a P/B Ratio of 10.87. 100% FREE. Do the numbers hold clues to what lies ahead for the stock? Based on CDXS analyst price targets, CDXS stock forecast is $26.86 (for a year from now). Codexis does not have a long track record of dividend growth. 1 year ago. Analyst recommendations provided by FactSet shows that the consensus forecast for Codexis Inc. (CDXS) is a “Buy”. The company issued revenue guidance of $82 million-$85 million, compared to the consensus revenue estimate of $83.27 million. View our full suite of financial calendars and market data tables, all for free. That means the average analyst price target for CDXS stock is $26.86. Codexis is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. Codexis has only been the subject of 3 research reports in the past 90 days. Analyst Price Target on CDXS. Codexis' management team includes the following people: Sr. VP of Strategic Devel. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. View analyst ratings for Codexis or view top-rated stocks. 25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. CDXS Stock Forecast. Free Signup : Top 50 … Limited Time Only. Codexis Inc. Stock Price Forecast, "CDXS" Predictons for2021 Disclaimer. Name Not Important predicted that CDXS for 2019-04-29 is going $18.93 (-25.18%) 1 year ago. $27.99. View which stocks have been most impacted by COVID-19. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Notable Dividend: Unable to evaluate CDXS… Please log in to your account or sign up in order to add this asset to your watchlist. See Codexis, Inc. (CDXS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Codexis has a market capitalization of $1.26 billion and generates $68.46 million in revenue each year. You can opt out at any time. CDXS -- USA Stock : USD 23.90 1.01 4.41% : Codexis Stock Forecast is based on your current time horizon. The extremes of the forecast give a target low and a target high price of $23 and $30 respectively. Compare Top Brokerages Here. Codexis Inc. quote is equal to 18.970 USD at 2021-05-20. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. The consensus price target of analysts on Wall Street is $26.86, which implies an increase of 9.1% to the stock’s current value. Overall. Codexis Inc. CDXS. Codexis has received 322 “outperform” votes. Codexis, Inc. Common Stock (CDXS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Earnings for Codexis are expected to decrease in the coming year, from ($0.47) to ($0.52) per share. View insider buying and selling activity for Codexis or view top insider-selling stocks. Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR). TradingView. Codexis Inc Stock Predictions. Since then, CDXS stock has increased by 93.3% and is now trading at $19.56. In the meantime, none analyst(s) believe the stock … As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Codexis' stock was trading at $10.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). 8 analysts offering their recommendations for the stock have an average rating of 1.60, where 0 rate it as a Hold and 0 think it is a “Overweight”. Investors can use this forecasting interface to forecast Codexis historical stock prices and determine the direction of Codexis's future trends based on various well-known forecasting models. 5 equities research analysts have issued twelve-month price targets for Codexis' shares. Fundamental company data provided by Zacks Investment Research. Learn about financial terms, types of investments, trading strategies and more. About the Codexis, Inc. stock forecast. Receive a free world-class investing education from MarketBeat. Find market predictions, CDXS financials and market news. Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS). CNN Sans™ & © 2016 Cable News Network. The consensus among Wall Street equities research analysts is that investors should "buy" Codexis stock. Data is currently not available. TradingView . Codexis Stock Predictions. Only 10.20% of the stock of Codexis is held by insiders. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Codexis (NASDAQ:CDXS) Earnings Information Codexis last released its quarterly earnings results on May 6th, 2021. View all of CDXS's competitors. Want to see which stocks are moving? 8 of the analysts rate the stock as a “Buy”. Codexis's earnings in 2021 is -$25,426,000.On average, 4 Wall Street analysts forecast CDXS's earnings for 2021 to be $-39,284,437, with the lowest CDXS earnings forecast at $-52, On average, they expect Codexis' share price to reach $26.60 in the next twelve months. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 One share of CDXS stock can currently be purchased for approximately $19.56. All rights reserved. All times are ET. A Warner Media Company. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. A quick review shows that CDXs price is currently 16.05% off the SMA20 and 3.8% off the SMA50. Codexis updated its FY 2021 earnings guidance on Thursday, May, 20th. MarketBeat just released five new stock ideas, but Codexis wasn't one of them. Factset: FactSet Research Systems Inc.2019. Ticker Trading Ideas Educational Ideas Scripts People. CDXS Stock Forecast - Is CDXS a buy or sell? Profile Profile Settings Account and Billing Referred friends Coins … Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. View which stocks have been most impacted by COVID-19. Get daily stock ideas top-performing Wall Street analysts. Scan for strong stocks. Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings results on Thursday, May, 6th. The prediction is based on 7 analyst estimates. © 2020 Cable News Network. & GM of Biotherapeutics, Ph.D., Sr. VP of Pharmaceutical Devel., Quality & Regulatory, Start Your Risk-Free Trial Subscription Here, Deere Moves Higher Early Friday After Boosting Earnings Outlook, Palo Alto Networks Accelerates To New Highs, Stellantis Stock is an Under the Radar Robotics and EV Automation Play, Take-Two Stock Is Putting Bullish Investors at a Crossroads. Dividend Yield vs Market. CDXS : 12.00 (-0.74%) SRRA : 10.75 (-1.47%) The Global Pharmaceutical Intermediates Market is expected to grow from USD 22,197.09 Million in 2018 to USD 36,876.78 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.52% PR Newswire - PRF - Thu Jun 4, 9:30AM CDT. All rights reserved. What is CDXS stock forecast (i.e., prediction)? The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.06. (Add your “underperform” vote.). 3. Codexis, Inc. Common Stock (CDXS) Nasdaq Listed. 8 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. This suggests a possible upside of 36.0% from the stock's current price. Codexis' stock was trading at $10.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Codexis, Inc. (CDXS) stock forecast and price target. Apart from that, the company came lowering its revenue forecast … © American Consumer News, LLC dba MarketBeat® 2010-2021. Codexis Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. You may vote once every thirty days. The company added +67.14% of value to its shares in past 6 months, showing an annual growth rate of 52.5% while that of industry is 7.9. If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. Specifically, they have bought $0.00 in company stock and sold $2,053,803.00 in company stock. Their forecasts range from $16.00 to $32.00. See what's happening in the market right now with MarketBeat's real-time news feed. With a 5-year investment, the revenue is expected to be around +27.01%. Analyst Predictions. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. All rights reserved. Your current $100 investment may be up to $127.01 in 2026. Codexis does not currently pay a dividend. Codexis Inc has risen higher in 5 of those 10 years over the subsequent 52 week period, corresponding to a historical accuracy of 50 % Is Codexis Inc Stock … P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short-term (time horizon: 2 weeks) CODEXIS INC share price prediction for 2021-07-02 with daily closed price projections Key Facts Symbol CDXS … 0 analysts have rated the stock … View Codexis' earnings history. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. What is Codexis's current dividend yield, its reliability and sustainability? Codexis is headquartered at 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. In the medium term (3months), CDXS's stock … For Codexis stock forecast 2021, 8 predictions are offered for each month of 2021 with average Codexis stock forecast of $23.56, a high forecast of $23.75, and a low forecast … View institutional ownership trends for Codexis. Add to Watchlist. Dividend. zsyontekleri predicted that CDXS for 2019-04-08 is going $21.88 (-13.52%) Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. John J. Nicols has an approval rating of 68% among Codexis' employees. The average price target represents a 62.02% increase from the last price of $17.59. Find real-time CDXS - Codexis Inc stock quotes, company profile, news and forecasts from CNN Business. As of 2021 May 15, Saturday current price of CDXS stock is 18.290$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Codexis stock price as been showing a rising tendency so we believe that similar market … MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. The biotechnology company had revenue of $18 million for the quarter, compared to the consensus estimate of $14.85 million. CDXS stock was sold by a variety of institutional investors in the last quarter, including Telemark Asset Management LLC, Janus Henderson Group PLC, Millennium Management LLC, Goldman Sachs Group Inc., First Light Asset Management LLC, Union Square Park Capital Management LLC, Assenagon Asset Management S.A., and State of New Jersey Common Pension Fund D. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, John J Nicols, and Patrick Y Yang. The firm's revenue was up 23.3% compared to the same quarter last year. Sign up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Should I buy or sell CDXS? Over the next 52 weeks, Codexis Inc has on average historically risen by 32.7 % based on the past 10 years of stock performance. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. Codexis Bags Novartis as Software Customer, Stays Course in First Quarter The small-cap biotech now has three of the top 10 pharmaceutical companies using its protein engineering platform technology. High institutional ownership can be a signal of strong market trust in this company. Find out now with a free analysis on Codexis. CDXS Stock Analysis Overview. Wall Street analysts have given Codexis a "Buy" rating, but there may be better buying opportunities in the stock market. CDXS Stock Analysis - [Full Report] Free Signup: Advanced stock screener. Forecast Cash Runway: CDXS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 36.7% each year. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. The biotechnology company reported ($0.14) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.06. Codexis' stock is owned by a number of institutional and retail investors. Morningstar Rating. What More Does Golden Nugget Have to Prove? May 20 / GuruFocus News - Paid Partner Content, Codexis Inc (CDXS) President and CEO John J Nicols Sold $1.3 million of Shares, Worst Way To Retire: Do Any Of These Things, If You Don't Know What "Fiduciary" Means, Retirement Could be Harder, The Retirement Secret They Don't Want You To Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. This price target is based on 3 analysts offering 12 month price targets for Codexis in the last 3 months. Codexis Inc. (CDXS) Analyst Forecasts. Find market predictions, CDXS financials and market news. Name Not Important predicted that CDXS for 2019-04-22 is going $20.18 (-20.24%) 1 year ago. Get short term trading ideas from the MarketBeat Idea Engine. Vote “Underperform” if you believe CDXS will underperform the S&P 500 over the long term. Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates Codexis (CDXS) delivered earnings and revenue surprises of 30.00% and 21.09%, respectively, for the quarter ended March 2021. There are currently 5 buy ratings for the stock. Codexis trades on the NASDAQ under the ticker symbol "CDXS.". ), Codexis has received 335 “underperform” votes. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. The low price target for CDXS … Forecast for Fri 02 Jul 2021 price 16.82 CODEXIS INC stock price forecast for further price development up to 0.02% (time horizon: 1 day) and price target of 19.34 USD. As a result, CDXS is trading at a discount of 21.85% off the target high and -6.58% off … In the short term (2weeks), CDXS's stock price should outperform the market by 3.75%.During that period the price should oscillate between -6.12% and +10.91%.. Identify stocks that meet your criteria using seven unique stock screeners. MarketBeat thinks these five companies may be even better buys.View MarketBeat's top stock picks here. Codexis Inc (CDXS) is a Buy Codexis Inc Stock Forecast . Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Get an edge in the market with our real-time CDXS stock forecast. Codexis has received a consensus rating of Buy. View our earnings forecast for Codexis. Top institutional investors include ARK Investment Management LLC (9.74%), Baillie Gifford & Co. (9.20%), BlackRock Inc. (7.95%), Gilder Gagnon Howe & Co. LLC (3.81%), Telemark Asset Management LLC (3.81%) and William Blair Investment Management LLC (3.65%). Since then, CDXS shares have increased by 80.7% and is now trading at $18.29. CDXS -- USA Stock : USD 19.51 0.50 2.50% : Codexis Stock Forecast is based on your current time horizon. Rating as of May 18, 2021. ET View Interactive CDXS Charts According to analysts' consensus price target of $26.60, Codexis has a forecasted upside of 36.0% from its current price of $19.56. The average price target represents a -7.99% upside from the last price of $23.91. Shares of CDXS can be purchased through any online brokerage account. The average price target is $28.50 with a high forecast of $32.00 and a low forecast of $26.00. The average price target is $22.00, with a high forecast of $29.00 and a low forecast of $16.00. EN. CMTX - Thu … 4 days ago - Zacks Investment Research Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. cdxs $18.29 $0.70 4.0% Price as of May 14, 2021, 4:00 p.m. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Codexis has received 50.99% “underperform” votes from our community. Vote “Outperform” if you believe CDXS will outperform the S&P 500 over the long term. 7 Stocks That Can Help You Profit From Summer Shortages, 7 Retailers That Are Bucking the E-Commerce Trend, 7 Cyclical Stocks That Can Help You Play Defense, 7 Stocks That Could Benefit From a Capital Gains Tax Hike, 7 Forever Stocks That Are Never Bad to Buy, 7 Stocks That Still Have Upside For Investors to Buy, 7 Precious Metals Stocks That Will Keep Your Portfolio On Trend, 7 Bellwether Stocks Signaling a Return to Normal, 7 Electric Vehicle (EV) Stocks That Are Ready to Rebound, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, Codexis Inc (CDXS) President and CEO John J Nicols Sold $1.3 million of Shares - Yahoo Finance, Codexis (NASDAQ:CDXS) Issues FY 2021 Earnings Guidance, Global Enzymes Market By Source, By Type, By Reaction Type, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027 - Yahoo Finance, Codexis to Participate in Upcoming Virtual Healthcare Conferences - GlobeNewswire, Codexis (NASDAQ:CDXS) Updates FY 2021 Earnings Guidance, This is Why a Healthy Gut is Crucial for Your Wellbeing - Baystreet.ca, Oversold Conditions For Codexis (CDXS) - Nasdaq, Codexis (NASDAQ:CDXS) Shares Gap Down to $19.34, Notable Two Hundred Day Moving Average Cross - CDXS - Nasdaq, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Nasdaq 100. Statistics highlight that Codexis, Inc. is scoring comparatively higher than the scores of other players of the relevant industry. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang. CDXS : Codexis stock forecast, predictions, and share price target for 2021, 2022 (1 year) to 2025, 2026 (5 year) to 2030, and 2031 (10 year) From AI system, total return is 2081.37% from 1669 forecasts. CODEXIS INC stock prediction: up to 19.34 USD CDXS stock price prognosis STOCK. The RSI metric on the 14-day chart is currently showing 58.63, and weekly volatility stands at 9.3%. Based on our forecasts, a long-term increase is expected, the "CDXS" stock price prognosis for 2026-05-18 is 24.094 USD. Codexis employs 181 workers across the globe. Based on 4 analysts offering 12 month price targets for Codexis in the last 3 months. In the past three months, Codexis insiders have sold more of their company's stock than they have bought. Learn more about MarketBeat. (Add your “outperform” vote. Codexis, Inc. (CDXS) estimates and forecasts.
Weather For Thursday, Shin Splints After Acl Surgery, You Mean Alot To Me Meaning In Urdu, Argentina Pandemic News, Thyroid Calculator Uk, Bts Stats Twitter, How To Report A Fake Non Profit, Hypothyroidism Management Guidelines, Barb And Star Song In Trailer,